Semax + Selank: A Two-Peptide Nootropic Stack

Research use disclaimer: Crown Peptides supplies Semax and Selank as laboratory research compounds only. They are not approved by the FDA or MHRA for use in the US or UK, and our products are not intended for human consumption, diagnosis, treatment, cure or prevention of any disease. The discussion below summarises published scientific literature for researchers and students of pharmacology.

In the early 1980s, a team at the Institute of Molecular Genetics in Moscow was working on a problem that sounds almost too neat to be true: could you take a fragment of a hormone the body already makes, tweak it just enough to survive contact with the enzymes that would normally destroy it in seconds, and end up with something that still does the hormone’s job — just longer, and just where you want it? The answer, twice over, was yes. The first peptide out of that work was Semax. The second, built on the same chemical trick a few years later, was Selank. Today the two are sold together almost as often as they’re sold apart, and understanding why means understanding what makes each one tick on its own first — because unlike most peptide “stacks,” this one wasn’t assembled after the fact by a marketing team looking for a plausible-sounding combination. It was built into the compounds from the start.

In brief:

• Semax and Selank are two separate, structurally unrelated heptapeptides engineered by the same Russian research programme, using the same stabilising modification, against two different neurological targets.
• Semax is built from a fragment of ACTH and is studied for dopaminergic, serotoninergic and neurotrophic (BDNF) activity linked to cognitive drive and focus.
• Selank is built from a fragment of tuftsin and is studied for enkephalin-protective, anxiolytic activity that doesn’t rely on GABA-receptor binding the way benzodiazepines do.
• Both have real human clinical trial histories in Russia — for stroke recovery (Semax) and generalised anxiety disorder (Selank) — though neither is FDA- or MHRA-approved.
• There’s no dedicated trial testing the two together; the case for pairing them rests on their complementary individual mechanisms.

The Lab That Built Peptides on Purpose

Most of the peptides that dominate research-compound catalogues today were discovered more or less by accident — isolated from tissue, gut, or venom, and only later synthesised for study. Semax and Selank didn’t happen that way. They were designed, on purpose, by a research programme built around a specific hypothesis: that short fragments of much larger, well-understood biological molecules could retain the parent molecule’s most useful signalling activity while shedding the parts responsible for its systemic hormonal or immunological effects. The team behind this work, led by biochemist Nikolai Myasoedov at what is now the Institute of Molecular Genetics of the Russian Academy of Sciences, had a long-running interest in ACTH and its fragments going back to Soviet-era neuropeptide research in the 1970s.

The starting point for Semax was ACTH(4-10) — a seven-residue stretch cut out of the middle of adrenocorticotropic hormone, the pituitary hormone best known for driving cortisol release from the adrenal glands. Isolated fragments like this had been studied for decades because they seemed to retain central nervous system activity without triggering the adrenal cascade — but they vanished from the bloodstream almost as fast as they were injected, chewed apart by peptidase enzymes within minutes. Myasoedov’s fix was to attach a short Pro-Gly-Pro sequence to the fragment’s C-terminus, a modification that physically blocks the enzymes that would otherwise degrade it. The result, patented and first studied through the 1980s, was Semax: the ACTH fragment’s central activity, minus its short half-life.

This wasn’t an isolated one-off project, either. Myasoedov’s group worked within a broader Soviet and post-Soviet research tradition around “regulatory peptides” — the idea that a huge share of physiology, from stress response to immune signalling to memory formation, is coordinated by short peptide messengers that could, in principle, be isolated, minimised down to their active core, and redeployed as research tools or therapeutics in their own right. That tradition produced a whole family of compounds beyond just Semax and Selank, but these two remain among the clearest, most cited demonstrations of the underlying method actually working: take a fragment already known to carry a specific biological signal, stabilise it against rapid clearance, and end up with something a laboratory can dose, measure and study on a practical timescale.

A few years later, the same lab applied the identical stabilisation trick to a completely different starting material: tuftsin, a naturally occurring tetrapeptide fragment of immunoglobulin G best known for its role in immune cell activation, and one that carried its own, less-studied history of central nervous system effects. Adding the same Pro-Gly-Pro tail produced Selank — chemically unrelated to Semax at the sequence level, but built from the identical engineering playbook, by the identical team, to solve the identical stability problem. That shared parentage is why the two are so frequently discussed side by side: they aren’t a coincidental pairing dreamed up by a supplement marketer, they’re two outputs of the same purpose-built stabilisation platform, developed against two deliberately different neurological targets.

Semax: The Drive Side of the Equation

Semax’s research profile centres on the central nervous system pathways you’d expect from an ACTH-derived compound, but with a twist: rather than working through the classical corticosteroid stress axis, it appears to act largely independently of it, engaging dopaminergic and serotoninergic signalling directly. A rodent study from the Russian Academy of Sciences found that Semax administration measurably activated both dopamine and serotonin systems in the brain, framing it specifically as a nootropic-acting ACTH(4-10) analogue rather than a conventional hormone mimetic (Eremin et al., 2005). That distinction matters for how researchers interpret its cognitive effects — this isn’t a peptide working through adrenal stress hormones, it’s one working through the same monoamine systems targeted by a huge share of conventional cognition-focused pharmacology.

Beyond monoamine signalling, a separate thread of rodent research has explored Semax’s effects on neurotrophic factors — specifically its influence on hippocampal expression of brain-derived neurotrophic factor and its receptor, a pathway heavily implicated in synaptic plasticity and memory consolidation across neuroscience more broadly. That kind of neurotrophic angle is one of the more mechanistically interesting threads in nootropic peptide research generally, because it points toward a plausible route from short-term peptide exposure to a longer-lasting change in neural signalling, rather than a purely transient pharmacological bump.

What sets Semax apart from most compounds discussed in research-peptide circles is that its evidence base doesn’t stop at rodent models. It’s one of the few peptides in this category with a genuine human clinical research trail, and it’s registered as a prescription nasal-drop medicine in Russia for specific neurological indications, including recovery in the acute phase after ischaemic stroke. A clinical study following stroke patients at different disease stages found measurable neurological recovery associated with Semax treatment as part of standard post-stroke management (Gusev et al., 2018). It’s worth being precise about what that does and doesn’t establish: Russian regulatory registration for a specific clinical formulation and indication is not the same thing as FDA approval in the US or MHRA approval in the UK, where Semax remains firmly in unapproved research-compound territory. What it does establish is a depth of clinical research history that’s genuinely unusual for a compound in this space — Semax isn’t a peptide known only from cell culture and rodent cages.

Selank: The Calm Side of the Equation

If Semax’s research story is about drive and plasticity, Selank’s reads almost like its mirror image: calm, without the blunting that comes with classical sedatives. As a tuftsin analogue, Selank’s proposed mechanism runs through the enkephalin system rather than through the monoamine pathways Semax engages. An early mechanistic study found that Selank inhibits the enzymes responsible for breaking down enkephalins — the body’s own opioid-like peptides, closely tied to mood and stress regulation — and proposed this enzyme-inhibition effect as a plausible explanation for Selank’s anxiolytic activity in animal models (Zozulya et al., 2001). By protecting the body’s own calming peptides rather than introducing an external sedative mechanism, Selank’s research profile stands apart from classical anxiolytics — and that distinction is a large part of why it continues to draw fresh research interest decades after its initial development.

As with Semax, that mechanistic promise didn’t stay confined to animal models. A randomised controlled study from the same Moscow research group evaluated Selank in patients diagnosed with generalised anxiety disorder and neurasthenia, examining both its clinical efficacy and its proposed underlying mechanisms directly in a human trial population (Zozulia et al., 2008). As with Semax’s stroke research, this trial was conducted and published within the Russian clinical research and regulatory system rather than under FDA or MHRA oversight, so it’s best read as evidence about Selank’s biological activity and its research trajectory, not as a licensing pathway that extends anywhere else. More recent rodent work has continued to expand Selank’s research profile in other directions too, including studies probing its effects on withdrawal physiology — a sign that interest in the compound’s broader neuromodulatory activity, beyond anxiety research specifically, is still actively growing.

Why Researchers Pair Them

Put the two research profiles side by side and the logic behind pairing them becomes fairly obvious. Semax’s dopaminergic and neurotrophic-linked activity points toward focus, drive and cognitive processing. Selank’s enkephalin-protective, anxiolytic profile points toward calm without sedation. A stimulant-leaning compound and an anxiolytic-leaning compound, engineered by the same lab using the same stabilisation chemistry, studied across overlapping but genuinely distinct neurological systems — it’s not hard to see why researchers interested in cognitive performance as a whole system, rather than a single isolated pathway, would want to study the two together rather than in isolation. Combination research protocols in the nootropic peptide space are still relatively uncommon precisely because most compounds don’t come with this kind of built-in, deliberately engineered complementarity.

There’s a practical dimension to this too. Researchers designing a cognitive-performance protocol that only addresses drive risk building a study population that reports improved task engagement alongside heightened subjective stress — a confound that can make it genuinely difficult to separate a real cognitive effect from an anxiety-driven change in effort or attention. Pairing a compound associated with dopaminergic drive with one associated with anxiolysis, rather than studying either variable in isolation, gives researchers a more realistic model of how cognitive performance actually behaves outside a single-variable lab setup — which is one reason the Semax and Selank combination specifically has become a reference point for how researchers think about stacking cognitive and stress-pathway peptides more generally, not just for this pair.

A note on informal reports. Accounts from individuals using Semax and Selank outside controlled research settings do circulate online. They are not research data, cannot be verified and are not a basis for any conclusion about the compound. Crown Peptides supplies Semax and Selank for in vitro laboratory research only and does not condone or encourage personal or human use of any research compound.

What Stability Actually Buys You in a Research Protocol

It’s worth dwelling on why peptidase resistance was the specific problem Myasoedov’s team set out to solve, because it explains a lot about how Semax and Selank behave in a research setting today. Most short regulatory peptides — the messenger molecules the body uses for fast, local signalling — are deliberately short-lived. That’s a feature, not a bug, for their natural role: a signal that lingers too long stops being a signal and starts being background noise. But that same short half-life is exactly what makes a peptide difficult to study pharmacologically. If a compound is cleared from circulation within a minute or two of administration, researchers are left trying to characterise effects that may be driven as much by the timing and rate of a single brief pulse as by the peptide’s intrinsic pharmacology.

The Pro-Gly-Pro modification sidesteps that problem by making the peptide a poor substrate for the aminopeptidases that would otherwise clip residues off its exposed termini. That doesn’t make Semax or Selank immune to degradation altogether — no peptide is — but it meaningfully extends the window over which each compound remains intact and bioactive after administration, which in turn is what allows researchers to study dosing intervals, behavioural time-courses and dose-response relationships with a level of precision that native ACTH fragments or native tuftsin never permitted. It’s also the underlying reason both peptides are formulated and studied primarily via intranasal or subcutaneous routes rather than oral administration — peptide bonds generally, and this stabilised backbone specifically, still don’t survive the gastrointestinal tract’s more aggressive digestive enzymes.

Purity Matters More With Short, Engineered Peptides

Both Semax and Selank are heptapeptides — seven amino acids in length — which puts them at the shorter end of the peptides typically sold for research use. Short peptides bring their own purity challenges: synthesis byproducts, truncated sequences and deamidated variants are proportionally easier to introduce, and harder to separate out chromatographically, at this length than in a longer, more structurally distinct peptide. Because both Semax and Selank rely specifically on that engineered Pro-Gly-Pro terminal tail to resist enzymatic breakdown, a batch with even a minor synthesis error in that exact terminal sequence can behave very differently in research use than the peptide a given protocol actually calls for — which makes verified purity a genuinely mechanistic concern here, not just a generic quality-control checkbox.

Every Semax and Selank batch Crown Peptides supplies is manufactured against a batch-specific Certificate of Analysis, with identity confirmed by mass spectrometry and purity verified by HPLC — the standard combination for catching both compositional errors and truncated-sequence contaminants in short synthetic peptides. Full guidance on interpreting those reports, including what HPLC purity percentages and mass spec identity confirmation actually tell you about a given vial, is covered in our guide to reading a peptide Certificate of Analysis. Reconstitution and storage discipline matter just as much for a stabilised-but-still-short peptide like either of these — both should be reconstituted with bacteriostatic water and kept refrigerated or frozen between uses, since the engineered Pro-Gly-Pro stability buys resistance to enzymatic degradation, not immunity to heat, light or repeated freeze-thaw cycles. Lyophilised vials of both peptides should be stored frozen and shielded from light prior to reconstitution; once reconstituted, keeping vials refrigerated and minimising the number of freeze-thaw cycles they go through remains good practice for preserving peptide integrity over a research protocol’s full duration, exactly as it would for any other short synthetic peptide.

How This Fits Into the Broader Nootropic Research Picture

Cognitive-research peptides tend to get studied and discussed as if focus, memory, motivation and stress resilience were four separate boxes to tick off independently. In practice they’re tightly coupled systems — chronic stress measurably degrades memory consolidation, and cognitive underperformance is itself one of the more reliable triggers of anxious rumination. A research approach that only ever targets one node in that loop is working against the rest of the system, which is a large part of why interest has been shifting, across the nootropic peptide field generally, toward combinations that address more than one node at once rather than single-target compounds studied in isolation.

Semax and Selank happen to be an unusually clean test case for that broader shift, precisely because their individual mechanisms are already so well separated in the literature. Where many proposed nootropic stacks combine compounds with poorly characterised or overlapping mechanisms — making it genuinely difficult to attribute an observed effect to either ingredient — Semax’s dopaminergic and neurotrophic activity and Selank’s enkephalin-protective anxiolysis sit on largely independent pathways. That separation is exactly what makes the pairing useful as a research tool as well as a product: it gives investigators a combination where each half’s contribution can, at least in principle, be reasoned about separately even when the two are studied together.

It also explains why the Semax and Selank pairing tends to come up in a different context from most other peptide “stacks.” Many blend products on the research market group compounds together primarily on the strength of a shared target audience or a shared intended use case — recovery peptides bundled for recovery research, longevity peptides bundled for longevity research — without the individual components necessarily sharing a research history, a development lineage, or a well-defined relationship between their mechanisms. Semax and Selank didn’t arrive at their pairing that way. Their relationship predates any commercial blend product by decades: it’s baked into the shared engineering approach the original Moscow research programme used to build both compounds in the first place, which is a meaningfully different starting point for a research combination than two unrelated peptides being grouped together after the fact.

Frequently Asked Questions

Are Semax and Selank the same compound under two different names?

No. They’re structurally distinct peptides derived from entirely different parent molecules — Semax from ACTH(4-10), Selank from tuftsin — that happen to share the same Pro-Gly-Pro stabilising modification, developed by the same Russian research group. They’re studied for different, complementary neurological effects rather than being interchangeable versions of the same underlying compound.

Is Semax an approved medicine anywhere?

Semax is registered as a prescription nasal-drop medicine in Russia for specific neurological indications, including recovery after ischaemic stroke. That registration is specific to the Russian regulatory system; it does not extend to FDA approval in the US or MHRA approval in the UK, where Semax remains an unapproved research compound.

What does the research say about combining the two rather than studying them separately?

Formal head-to-head or combination trials are limited — most of the peer-reviewed literature on both Semax and Selank studies each compound individually. The case for pairing them currently rests on their complementary individual mechanisms — dopaminergic and neurotrophic activity for Semax, enkephalin-protective anxiolysis for Selank, rather than on dedicated combination trials.

Why do both peptides end in the same three amino acids?

The Pro-Gly-Pro sequence is a deliberate stabilising motif, not a coincidence inherited from their natural parent molecules. It was engineered onto both peptides specifically to slow their breakdown by peptidase enzymes, extending their functional half-life enough to make them viable, consistently reproducible research tools rather than compounds that degrade before they can be meaningfully studied.

Does Selank’s anxiolytic research overlap with classical benzodiazepine research?

Not mechanistically. Selank’s proposed activity runs through inhibition of enkephalin-degrading enzymes rather than through the GABA-receptor binding that defines benzodiazepine pharmacology. That’s one of the main reasons Selank keeps attracting comparative research interest — it offers investigators a route into anxiolytic activity through a mechanistically distinct pathway.

Why are so many of the human trials for these two peptides published in Russian-language journals?

Because that’s where the compounds were developed, registered and clinically tested. Semax and Selank went through the Russian drug registration and clinical trial system rather than the FDA or EMA pathway, so the bulk of the peer-reviewed human data sits in Russian medical journals — indexed on PubMed, and available in English abstract form, but reflecting a different regulatory process than compounds developed and trialled in the US or EU.

Are there other peptides that share this same Pro-Gly-Pro stabilisation approach?

Semax and Selank are the two best-characterised examples, and both came directly out of Myasoedov’s original research programme. The broader principle behind their design — stabilising a short bioactive fragment against rapid enzymatic clearance so it becomes viable to study — is a recognised approach in peptide pharmacology more generally, but Semax and Selank remain the most extensively published examples of it applied specifically to central nervous system research.

Where This Research Is Heading

Few peptide pairs in the current research-compound catalogue combine this level of mechanistic clarity, decades of published literature, and genuine human clinical trial history behind each half. Semax’s dopaminergic and neurotrophic-linked activity and Selank’s enkephalin-protective anxiolysis are two of the more thoroughly characterised, non-overlapping mechanisms in the entire nootropic peptide category — and that’s exactly why interest in studying them together, rather than in isolation, keeps growing rather than fading. For researchers building out cognitive and stress-pathway protocols, the Semax and Selank pairing remains one of the more scientifically grounded starting points available.

That’s a rare position for any pairing in this field to be in, and it’s part of why Semax and Selank keep showing up together in serious literature reviews rather than only in informal stacking guides. As research interest in multi-pathway cognitive protocols continues to grow, compounds with this level of individually documented mechanism — rather than combinations assembled purely on the strength of anecdote — are likely to remain the ones worth watching most closely. These informal reports are not research data, and Crown Peptides does not condone personal or human use of research compounds.

Crown Peptides supplies both compounds individually and as a combined Semax 5mg + Selank 5mg research peptide blend, with every batch backed by a certificate of analysis confirming identity and purity. For a closer look at either compound on its own, see our dedicated guides to Semax and Selank, or browse the full Crown Peptides research catalogue for related compounds.